Latest Articles

Publication Date
All News Scientific
Endometrial carcinosarcoma with multi-classifier molecular signature (MMRd-p53abn): A case report - EurekAlert!

Endometrial carcinosarcoma with multi-classifier molecular signature (MMRd-p53abn): A case report EurekAlert!

Published: Aug. 4, 2026, 7:14 p.m.
Read Full Article
Endometrial carcinosarcoma with multi-classifier molecular signature (MMRd-p53abn): A case report - eurekalert.org

Endometrial carcinosarcoma with multi-classifier molecular signature (MMRd-p53abn): A case report eurekalert.org

Published: Aug. 4, 2026, 7:14 p.m.
Read Full Article
Selinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer - Targeted Oncology

Selinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer Targeted Oncology

Published: July 31, 2026, 8:06 p.m.
Read Full Article
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - OncLive

Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer OncLive

Published: July 31, 2026, 5:22 p.m.
Read Full Article
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - onclive.com

Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer onclive.com

Published: July 31, 2026, 5:22 p.m.
Read Full Article
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - CancerNetwork

Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer CancerNetwork

Published: July 31, 2026, 2:37 p.m.
Read Full Article
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - cancernetwork.com

Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer cancernetwork.com

Published: July 31, 2026, 2:37 p.m.
Read Full Article
Selinexor Maintenance Displays Durable Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer - OncLive

Selinexor Maintenance Displays Durable Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer OncLive

Published: June 25, 2025, 9:58 p.m.
Read Full Article
The value of multi-sequence magnetic resonance imaging and whole-tumor apparent diffusion coefficient histogram analysis in differentiating p53 abnormal from non-p53 abnormal endometrial carcinoma - Frontiers

The value of multi-sequence magnetic resonance imaging and whole-tumor apparent diffusion coefficient histogram analysis in differentiating p53 abnormal from non-p53 abnormal endometrial carcinoma Frontiers

Published: April 15, 2025, 2:55 p.m.
Read Full Article
Cold atmospheric plasma drives USP49/HDAC3 axis mediated ferroptosis as a novel therapeutic strategy in endometrial cancer via reinforcing lactylation dependent p53 expression - Journal of Translational Medicine

Cold atmospheric plasma drives USP49/HDAC3 axis mediated ferroptosis as a novel therapeutic strategy in endometrial cancer via reinforcing lactylation dependent p53 expression Journal of Translational Medicine

Published: April 15, 2025, 11:54 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!